Kehonkoostumuksen ja aineenvaihdunnan tutkimus.
GLP-1-hylly ja kaikki siihen liittyvä: semaglutidi, tirtsepatidi ja retatrutidi esitäytetyissä kynissä, sekä tesamorelin, AOD9604, tesofensiini ja metaboliset seokset. Tämä on katalogimme voimakkaimmin tutkittu ryhmä, ja tutkimusosastomme käsittelee kunkin yhdisteen taustalla olevia tutkimuksia sen sijaan, että vain tiivistäisi markkinointimateriaalia.
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%
DEAL −15%Ennen kuin tilaat
GLP-1Tirzepatide: what SURMOUNT-1 and SURMOUNT-2 actually showed
Two 72-week placebo-controlled trials, 3,477 participants between them — one in obesity without diabetes, one in obesity with type 2 diabetes. The published weight-loss figures, dose by dose, and where the data stop.
PerformanceExercise mimetics: what AICAR, SLU-PP-332 and 5-Amino-1MQ have actually done, and in what species
One of these three has been given to 3,080 humans — and the trial was stopped for futility. The other two have never been given to a human at all. All three are sold on the same phrase, and the phrase comes from one mouse treadmill experiment in 2008.
MetabolicTesofensine: a phase 2 result that never became a phase 3 paper
The 2008 Lancet trial is real, and the numbers in it are large. What followed is the part nobody quotes — an Expression of Concern from the journal, no published phase 3 anywhere in the indexed literature, and no approval in the EU or the US.